Clinical Trial Update: BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial update for BIBR-1048 in preventing venous thromboembolism after elective total hip or knee replacement; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• BIBR 1048

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Venous Thromboembolism | Phase 2 | Status: COMPLETED | Results posted: 2010-12-16